381 related articles for article (PubMed ID: 28067867)
1. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
Taylor RA; Fraser M; Livingstone J; Espiritu SM; Thorne H; Huang V; Lo W; Shiah YJ; Yamaguchi TN; Sliwinski A; Horsburgh S; Meng A; Heisler LE; Yu N; Yousif F; Papargiris M; Lawrence MG; Timms L; Murphy DG; Frydenberg M; Hopkins JF; Bolton D; Clouston D; McPherson JD; van der Kwast T; Boutros PC; Risbridger GP; Bristow RG
Nat Commun; 2017 Jan; 8():13671. PubMed ID: 28067867
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
[TBL] [Abstract][Full Text] [Related]
3. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
Petrovics G; Price DK; Lou H; Chen Y; Garland L; Bass S; Jones K; Kohaar I; Ali A; Ravindranath L; Young D; Cullen J; Dorsey TH; Sesterhenn IA; Brassell SA; Rosner IL; Ross D; Dahut W; Ambs S; Figg WD; Srivastava S; Dean M
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):406-410. PubMed ID: 30542053
[TBL] [Abstract][Full Text] [Related]
4. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
Khani F; Wobker SE; Hicks JL; Robinson BD; Barbieri CE; De Marzo AM; Epstein JI; Pritchard CC; Lotan TL
J Pathol; 2019 Sep; 249(1):79-89. PubMed ID: 30993692
[TBL] [Abstract][Full Text] [Related]
5. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
[TBL] [Abstract][Full Text] [Related]
6. High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
Castro E; Jugurnauth-Little S; Karlsson Q; Al-Shahrour F; Piñeiro-Yañez E; Van de Poll F; Leongamornlert D; Dadaev T; Govindasami K; Guy M; Eeles R; Kote-Jarai Z;
Ann Oncol; 2015 Nov; 26(11):2293-300. PubMed ID: 26347108
[TBL] [Abstract][Full Text] [Related]
7. The influence of BRCA2 mutation on localized prostate cancer.
Taylor RA; Fraser M; Rebello RJ; Boutros PC; Murphy DG; Bristow RG; Risbridger GP
Nat Rev Urol; 2019 May; 16(5):281-290. PubMed ID: 30808988
[TBL] [Abstract][Full Text] [Related]
8. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
Lozano R; Salles DC; Sandhu S; Aragón IM; Thorne H; López-Campos F; Rubio-Briones J; Gutierrez-Pecharroman AM; Maldonado L; di Domenico T; Sanz A; Prieto JD; García I; Pacheco MI; Garcés T; Llacer C; Romero-Laorden N; Zambrana F; López-Casas PP; Lorente D; Mateo J; Pritchard CC; Antonarakis ES; Olmos D; Lotan TL; Castro E
Eur J Cancer; 2021 Apr; 147():74-83. PubMed ID: 33626496
[TBL] [Abstract][Full Text] [Related]
9. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
[TBL] [Abstract][Full Text] [Related]
10. ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia.
Han B; Suleman K; Wang L; Siddiqui J; Sercia L; Magi-Galluzzi C; Palanisamy N; Chinnaiyan AM; Zhou M; Shah RB
Am J Surg Pathol; 2010 Apr; 34(4):478-85. PubMed ID: 20220513
[TBL] [Abstract][Full Text] [Related]
11. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
Lozano R; Castro E; Lopez-Campos F; Thorne H; Ramirez-Backhaus M; Aragon IM; Cendón-Florez Y; Gutierrez-Pecharroman A; Salles DC; Romero-Laorden N; Lorente D; González-Peramato P; Calatrava A; Alonso C; Anido U; Arévalo-Lobera S; Balmaña J; Chirivella I; Juan-Fita MJ; Llort G; Y Cajal TR; Almagro E; Alameda D; López-Casas PP; Herrera B; Mateo J; Pritchard CC; Antonarakis ES; Lotan TL; Rubio-Briones J; Sandhu S; Olmos D
Eur J Cancer; 2023 May; 185():105-118. PubMed ID: 36972661
[TBL] [Abstract][Full Text] [Related]
12. Management of a Prostate Cancer Patient With Inherited Germline BRCA1 and BRCA2 Mutations: A Case Report.
Hemal S; DeWitt-Foy M; Klein EA
Urology; 2021 Jul; 153():129-131. PubMed ID: 33556450
[TBL] [Abstract][Full Text] [Related]
13. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
Lee BH
Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
[TBL] [Abstract][Full Text] [Related]
14. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
Chua MLK; Lo W; Pintilie M; Murgic J; Lalonde E; Bhandari V; Mahamud O; Gopalan A; Kweldam CF; van Leenders GJLH; Verhoef EI; Hoogland AM; Livingstone J; Berlin A; Dal Pra A; Meng A; Zhang J; Orain M; Picard V; Hovington H; Bergeron A; Lacombe L; Fradet Y; Têtu B; Reuter VE; Fleshner N; Fraser M; Boutros PC; van der Kwast TH; Bristow RG
Eur Urol; 2017 Nov; 72(5):665-674. PubMed ID: 28511883
[TBL] [Abstract][Full Text] [Related]
15. Elucidation of the Genomic-Epigenomic Interaction Landscape of Aggressive Prostate Cancer.
Kumar Mamidi TK; Wu J; Hicks C
Biomed Res Int; 2021; 2021():6641429. PubMed ID: 33511206
[TBL] [Abstract][Full Text] [Related]
16. Germline BLM mutations and metastatic prostate cancer.
Ledet EM; Antonarakis ES; Isaacs WB; Lotan TL; Pritchard C; Sartor AO
Prostate; 2020 Feb; 80(2):235-237. PubMed ID: 31816118
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
Zhao J; Sun G; Zhu S; Dai J; Chen J; Zhang M; Ni Y; Zhang H; Shen P; Zhao X; Zhang B; Pan X; Nie L; Yin X; Liang J; Zhang X; Wang Z; Zhu X; Liao B; Liu Z; Armstrong CM; Gao AC; Huang H; Chen N; Zeng H
BJU Int; 2022 Mar; 129(3):345-355. PubMed ID: 34185954
[TBL] [Abstract][Full Text] [Related]
18. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
19. The role of BRCA1 and BRCA2 in prostate cancer.
Castro E; Eeles R
Asian J Androl; 2012 May; 14(3):409-14. PubMed ID: 22522501
[TBL] [Abstract][Full Text] [Related]
20. Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.
Decker B; Karyadi DM; Davis BW; Karlins E; Tillmans LS; Stanford JL; Thibodeau SN; Ostrander EA
Am J Hum Genet; 2016 May; 98(5):818-829. PubMed ID: 27087322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
